ELUT vs OSBC vs NVCR vs MBWM vs IBCP

For growth investors, Old Second Bancorp, Inc.

(OSBC) is the stronger pick with 18. 1% revenue growth year-over-year, versus -49. 6% for Elutia Inc. (ELUT). Elutia Inc. (ELUT) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate Old Second Bancorp, Inc. (OSBC) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Elutia Inc.

(ELUT) is the cheapest at 0. 8x versus Old Second Bancorp, Inc. at 13. 0x. On forward P/E, Mercantile Bank Corporation is actually cheaper at 9. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Mercantile Bank Corporation wins at 0. 64x versus Independent Bank Corporation's 1. 85x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Mercantile Bank Corporation (MBWM) delivered a total return of +78.

4%, compared to -91. 4% for Elutia Inc. (ELUT). Over 10 years, the gap is even starker: OSBC returned +222. 2% versus ELUT's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elutia Inc.

(ELUT) is the lower-risk stock at -0. 06β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately -3730% more volatile than ELUT relative to the S&P 500. On balance sheet safety, Independent Bank Corporation (IBCP) carries a lower debt/equity ratio of 23% versus 114% for Mercantile Bank Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Old Second Bancorp, Inc.

(OSBC) is pulling ahead at 18. 1% versus -49. 6% for Elutia Inc. (ELUT). On earnings-per-share growth, the picture is similar: Elutia Inc. grew EPS 169. 4% year-over-year, compared to -13. 4% for Old Second Bancorp, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elutia Inc.

(ELUT) is the more profitable company, earning 434. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 434. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OSBC leads at 27. 9% versus -149. 8% for ELUT. At the gross margin level — before operating expenses — OSBC leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Mercantile Bank Corporation (MBWM) is the more undervalued stock at a PEG of 0. 64x versus Independent Bank Corporation's 1. 85x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Mercantile Bank Corporation (MBWM) trades at 9. 6x forward P/E versus 9. 8x for Old Second Bancorp, Inc. — 0. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, IBCP (3.

0% yield), MBWM (2. 8% yield), OSBC (1. 1% yield) pay a dividend. ELUT, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Elutia Inc.

(ELUT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 06)). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELUT: -93. 0%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ELUT (Healthcare) and OSBC (Financial Services) and NVCR (Healthcare) and MBWM (Financial Services) and IBCP (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ELUT is a small-cap deep-value stock; OSBC is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; MBWM is a small-cap deep-value stock; IBCP is a small-cap deep-value stock. OSBC, MBWM, IBCP pay a dividend while ELUT, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.